‘Where we are today in biology AI is similar to GPT in 2020’: An interview with the CEO of Africa’s biggest AI startup
- BioNTech acquired InstaDeep for over $550 million in January 2022.
- InstaDeep developed an early warning system for COVID-19 variants in collaboration with BioNTech.
- The startup's RiboMab project has become part of BioNTech's immunotherapy toolkit.
The acquisition of InstaDeep by BioNTech exemplifies a strategic move to integrate advanced AI capabilities into the biotech sector, which could lead to significant advancements in healthcare. However, the challenge remains to balance innovation with data privacy and security, especially in a field as sensitive as biotechnology. Ongoing discussions about the implications of such partnerships on the broader AI landscape and their potential to drive industry standards would be beneficial.
